The success of suzetrigine supports the goal of moving beyond relieving pain to doing so safely, without perpetuating cycles ...

Acute Pain Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035 The report provides a detailed analysis of the current acute pain marketed drugs and ...

After years of investment to upgrade its manufacturing capabilities, Pacira BioSciences figures it’s time to retire a facility that has been running for more than a decade. | After years spent ...

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...

Lilly buys SiteOne in a $1bn deal that would give it a rival to Vertex's approved painkiller Journavx, and a partnership on another programme.

Tris Pharma has set its sights on an FDA filing for non-opioid pain drug cebranopadol this year after hitting the mark in an abdominoplasty trial.

Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug is expensive, and many people can't get it yet.

Lower levels of certain vitamins and minerals were found to be associated with chronic pain in a study led by researchers at ...

An estimated one in four Americans suffers from chronic pain. For one in 10 of those sufferers, their pain is so intense, it ...

Treatment with HCCP led to significant improvements in pain, sleep quality, mood, and overall quality of life in patients with PNI.

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.

Discover why Vertex Pharmaceuticals outperforms amid biotech sector decline. Explore growth drivers, risks, and the ...